@article{oai:dmu.repo.nii.ac.jp:00001475,
 author = {Kiuchi, Kaori and Morita, Asuka and Ouchi, Motoshi and Otani, Naoyuki and Jutabha, Promsuk and Nohara, Masakatsu and Fukasawa, Ichio and Fujita, Tomoe and Anzai, Naohiko},
 issue = {1},
 journal = {Dokkyo Journal of Medical Sciences},
 month = {Mar},
 note = {Urate (uric acid) is the major inert end product of purine metabolism in humans. Since it is water soluble, it requires a membranous protein called transporter for its permeation across the plasma membrane. Increased blood urate level is often seen in preeclampsia, but its precise mechanism remains unknown. Syncytiotrophoblasts function as a barrier between maternal blood and fetal one so called “blood-placental barrier”. So far, the expression of several urate transporters was identified in these cells, but it is still unclear about their contribution to urate handling in blood-placental barrier. In this study, we investigated the expression of urate transporters and the properties of ［14C］urate transport in both JAR and JEG-3, human choriocarcinoma cells as a model of human placenta. Conventional PCR analysis revealed that both JAR and JEG-3 cells express strongly breast cancer resistance protein (BCRP/ABCG2) mRNA. Uptake of ［14C］urate by these cells is time-dependent with Na＋- and Cl－-independent and voltage-insensitive manner and is not inhibited by benzbromarone, a representative renal urate transport inhibitor. Then, we focused on BCRP which shows strong mRNA expression and found that these cells have urate efflux property that is sensitive to fumitremorgin C (FMC), a BCRP inhibitor. These results suggest that BCRP is one of the important components for urate handling in human placenta in pathophysiological condition such as preeclampsia.},
 pages = {31--38},
 title = {Characterization of Urate Transport System in JAR and JEG-3 Cells, Human Trophoblast-derived Cell Lines},
 volume = {44},
 year = {2017}
}